Role of Pseudomonas aeruginosa type III effectors in disease.
暂无分享,去创建一个
[1] D. Glidden,et al. Increased mortality of ventilated patients with endotracheal Pseudomonas aeruginosa without clinical signs of infection* , 2008, Critical care medicine.
[2] S. Lory,et al. Acquisition and Evolution of the exoU Locus in Pseudomonas aeruginosa , 2006, Journal of bacteriology.
[3] F. Sutterwala,et al. Immune recognition of Pseudomonas aeruginosa mediated by the IPAF/NLRC4 inflammasome , 2007, The Journal of experimental medicine.
[4] Jordi Rello,et al. Severe Infections Caused by Pseudomonas Aeruginosa , 2003, Perspectives on Critical Care Infectious Diseases.
[5] T. Sawa,et al. Effect of anti-PcrV antibody in a murine chronic airway Pseudomonas aeruginosa infection model , 2007, European Respiratory Journal.
[6] Jianjun Sun,et al. How bacterial ADP-ribosylating toxins recognize substrates , 2004, Nature Structural &Molecular Biology.
[7] R. Mallampalli,et al. Proapoptotic effects of P. aeruginosa involve inhibition of surfactant phosphatidylcholine synthesis Published, JLR Papers in Press, July 25, 2006. , 2006, Journal of Lipid Research.
[8] Gabriel Núñez,et al. Frontline : Critical role for Ipaf in Pseudomonas aeruginosa-induced caspase-1 activation , 2007 .
[9] K. Schey,et al. ADP-ribosylation of cyclophilin A by Pseudomonas aeruginosa exoenzyme S. , 2006, Biochemistry.
[10] J. Feix,et al. Identification of superoxide dismutase as a cofactor for the pseudomonas type III toxin, ExoU. , 2006, Biochemistry.
[11] G. Viboud,et al. Yersinia outer proteins: role in modulation of host cell signaling responses and pathogenesis. , 2005, Annual review of microbiology.
[12] Vincent T. Lee,et al. Activities of Pseudomonas aeruginosa Effectors Secreted by the Type III Secretion System In Vitro and during Infection , 2005, Infection and Immunity.
[13] J. Engel,et al. Pseudomonas aeruginosa type III-secreted toxin ExoT inhibits host-cell division by targeting cytokinesis at multiple steps , 2006, Proceedings of the National Academy of Sciences.
[14] J. Engel,et al. The ubiquitin ligase Cbl-b limits Pseudomonas aeruginosa exotoxin T-mediated virulence. , 2007, The Journal of clinical investigation.
[15] J. Musser,et al. Secreted bacterial phospholipase A2 enzymes: better living through phospholipolysis. , 2007, Trends in microbiology.
[16] A. Prince,et al. The Type III Toxins of Pseudomonas aeruginosa Disrupt Epithelial Barrier Function , 2007, Journal of bacteriology.
[17] J. Engel. Molecular Pathogenesis of Acute Pseudomonas Aeruginosa Infections , 2003 .
[18] J. Engel,et al. The ADP Ribosyltransferase Domain of Pseudomonas aeruginosa ExoT Contributes to Its Biological Activities , 2004, Infection and Immunity.
[19] Sophie Bleves,et al. The bacterial type VI secretion machine: yet another player for protein transport across membranes. , 2008, Microbiology.
[20] A. Hauser,et al. Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa. , 2001, Microbiology.
[21] J. Rello,et al. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. , 2002, Critical care medicine.
[22] Shouguang Jin,et al. ExoS of Pseudomonas aeruginosa induces apoptosis through a Fas receptor/caspase 8‐independent pathway in HeLa cells , 2006, Cellular microbiology.
[23] S. McColley,et al. Type III Secretion Phenotypes of Pseudomonas aeruginosa Strains Change during Infection of Individuals with Cystic Fibrosis , 2004, Journal of Clinical Microbiology.
[24] Yue Zhang,et al. Intracellular Trafficking of PseudomonasExoS, a Type III Cytotoxin , 2007, Traffic.
[25] J. Wiener-Kronish,et al. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury , 1999, Nature Medicine.
[26] D. Hume,et al. Effector ExoU from the Type III Secretion System Is an Important Modulator of Gene Expression in Lung Epithelial Cells in Response to Pseudomonas aeruginosa Infection , 2003, Infection and Immunity.
[27] K. Bieging,et al. A C-Terminal Domain Targets the Pseudomonas aeruginosa Cytotoxin ExoU to the Plasma Membrane of Host Cells , 2006, Infection and Immunity.
[28] J. Barbieri,et al. Pseudomonas aeruginosa ExoT ADP-ribosylates CT10 Regulator of Kinase (Crk) Proteins* , 2003, Journal of Biological Chemistry.
[29] J. Sun,et al. Pseudomonas aeruginosa ExoS and ExoT. , 2004, Reviews of physiology, biochemistry and pharmacology.
[30] S. Lynch,et al. Persistent infection with Pseudomonas aeruginosa in ventilator-associated pneumonia. , 2008, American journal of respiratory and critical care medicine.
[31] A. Wullaert,et al. The Pseudomonas aeruginosa Type III secretion system plays a dual role in the regulation of caspase-1 mediated IL-1β maturation , 2007, Journal of cellular and molecular medicine.
[32] T. Evans,et al. The Type III Pseudomonal Exotoxin U Activates the c-Jun NH2-Terminal Kinase Pathway and Increases Human Epithelial Interleukin-8 Production , 2006, Infection and Immunity.
[33] J. Engel,et al. The Pseudomonas aeruginosa type III secreted toxin ExoT is necessary and sufficient to induce apoptosis in epithelial cells , 2008, Cellular microbiology.
[34] D. Hassett,et al. Modulation of lung epithelial functions by Pseudomonas aeruginosa. , 2005, Trends in microbiology.
[35] David J. Evans,et al. Actin cytoskeleton disruption by ExoY and its effects on Pseudomonas aeruginosa invasion. , 2005, FEMS microbiology letters.
[36] D. Oxley,et al. Eukaryotic localization, activation and ubiquitinylation of a bacterial type III secreted toxin , 2006, Cellular microbiology.
[37] Qing Deng,et al. Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins. , 2008, Annual review of microbiology.
[38] Qing Deng,et al. Modulation of Host Cell Endocytosis by the Type III Cytotoxin, Pseudomonas ExoS , 2008, Traffic.
[39] Alan Aderem,et al. Cytoplasmic flagellin activates caspase-1 and secretion of interleukin 1β via Ipaf , 2006, Nature Immunology.
[40] D. Kalman,et al. RNAi Screen Reveals an Abl Kinase-Dependent Host Cell Pathway Involved in Pseudomonas aeruginosa Internalization , 2008, PLoS pathogens.
[41] M. Kosorok,et al. Early Immune Response to the Components of the Type III System of Pseudomonas aeruginosa in Children with Cystic Fibrosis , 2005, Journal of Clinical Microbiology.
[42] A. M. Saliba,et al. Eicosanoid‐mediated proinflammatory activity of Pseudomonas aeruginosa ExoU , 2005, Cellular microbiology.
[43] H. Baker,et al. c-Jun NH2-Terminal Kinase-Mediated Signaling Is Essential for Pseudomonas aeruginosa ExoS-Induced Apoptosis , 2003, Infection and Immunity.
[44] S. Lory,et al. Pseudolipasin A Is a Specific Inhibitor for Phospholipase A2 Activity of Pseudomonas aeruginosa Cytotoxin ExoU , 2006, Infection and Immunity.
[45] M. Saier,et al. Protein secretion systems of Pseudomonas aeruginosa and P fluorescens. , 2003, Biochimica et biophysica acta.
[46] A. Maresso,et al. Pseudomonas aeruginosa ExoS ADP‐ribosyltransferase inhibits ERM phosphorylation , 2007, Cellular microbiology.
[47] C. Ottmann,et al. Phosphorylation‐independent interaction between 14‐3‐3 and exoenzyme S: from structure to pathogenesis , 2007, The EMBO journal.
[48] S. Lory,et al. Identification of Small Molecule Inhibitors of Pseudomonas aeruginosa Exoenzyme S Using a Yeast Phenotypic Screen , 2008, PLoS genetics.
[49] Yue Zhang,et al. Intracellular Localization of Type III-delivered Pseudomonas ExoS with Endosome Vesicles* , 2007, Journal of Biological Chemistry.
[50] Samuel I. Miller,et al. An inhibitor of gram-negative bacterial virulence protein secretion. , 2008, Cell host & microbe.